8-K: BridgeBio Pharma Reports Positive Clinical Trial Progress and Secures $1.25 Billion in Funding

BridgeBio Pharma announced positive clinical trial updates, including the acceptance of a New Drug Application for acoramidis, and secured up to $1.25 billion in capital.

Summary

• BridgeBio Pharma reported its fourth quarter and full year 2023 financial results, along with key business updates.
• The company submitted a New Drug Application (NDA) to the FDA for acoramidis to treat transthyretin amyloid cardiomyopathy (ATTR-CM), which has been accepted for review with a PDUFA date of November 29, 2024.
• A Marketing Authorization Application (MAA) for acoramidis was also accepted by the European Medicines Agency (EMA).
• Clinical data from the ATTRibute-CM trial showed a significant separation between the placebo and acoramidis groups on a composite endpoint of all-cause mortality and cardiovascular-related hospitalization, starting at Month 3 and continuing through Month 30.
• A single-arm Phase 3 study in Japanese ATTR-CM patients showed no mortality over a 30-month acoramidis treatment period.
• The company's Phase 3 study of infigratinib for achondroplasia, PROPEL 3, continues to enroll with full enrollment expected in 2024.
• BridgeBio has partnered with Kyowa Kirin, granting them an exclusive license for infigratinib in Japan for skeletal dysplasias, receiving $100 million upfront, royalties up to the high twenties percent, and potential milestone payments.
• The Phase 3 studies for BBP-418 (FORTIFY) for limb-girdle muscular dystrophy type 2I and encaleret (CALIBRATE) for autosomal dominant hypocalcemia type 1 are also ongoing, with full enrollment expected in 2024 and topline data for encaleret expected in 2025.
• BridgeBio secured up to $1.25 billion in capital from Blue Owl and CPP Investments, including $500 million in cash for a 5% royalty on future global net sales of acoramidis and a $450 million credit facility.
• The company ended the quarter with $393 million in cash, cash equivalents, and short-term restricted cash, and $59 million in investments in equity securities.
• Revenue for the year ended December 31, 2023 was $9.3 million, compared to $77.6 million in the prior year, primarily due to a decrease in license revenue.
• Operating costs and expenses for the year ended December 31, 2023 were $616.7 million, compared to $589.9 million in the prior year, primarily due to increased R&D expenses.

Sentiment

Score: 8

Explanation: The document is largely positive due to the successful clinical trial results, regulatory progress, and significant funding secured. However, the high operating costs and net loss temper the overall sentiment slightly.

Positives

• The NDA for acoramidis was accepted by the FDA, with a PDUFA date set for November 29, 2024.
• The MAA for acoramidis was accepted by the EMA.
• Clinical trial data for acoramidis showed a significant and rapid benefit in reducing mortality and cardiovascular-related hospitalizations.
• The company secured a substantial $1.25 billion in funding, strengthening its financial position.
• The partnership with Kyowa Kirin provides a significant upfront payment and future revenue potential.
• The company has a strong cash position of $393 million.

Negatives

• Revenue decreased significantly from $77.6 million in 2022 to $9.3 million in 2023, primarily due to a decrease in license revenue.
• Operating costs and expenses increased to $616.7 million in 2023, compared to $589.9 million in 2022.
• The company reported a net loss of $653.2 million for the year ended December 31, 2023.

Risks

• The success of acoramidis is dependent on FDA and EMA approval, which is not guaranteed.
• Clinical trial results may not always translate to real-world outcomes.
• The company's financial performance is heavily reliant on the success of its pipeline and commercialization efforts.
• The company is subject to risks associated with drug development, regulatory approvals, and market competition.
• The company's operating costs are high, and it is currently operating at a loss.

Future Outlook

The company is focused on the potential launch of acoramidis, fully enrolling three ongoing Phase 3 clinical trials by the end of 2024, and reading out data from a Phase 1/2 trial in congenital adrenal hyperplasia later this year.

Management Comments

• Our focus this year is executing on the launch of acoramidis for patients with ATTR cardiomyopathy, said Neil Kumar, Ph.D., founder and CEO of BridgeBio.
• We are excited for this launch, as well as for the continued advancement of our late stage pipeline, which we hope will allow us to serve patients with genetic diseases both directly with the advancement of those medicines towards the market as well as by diversifying our top line revenue and enabling reinvestment into the R&D and business development opportunities that will allow us to be sustainable in the long term, said Brian Stephenson, Ph.D., CFA, Chief Financial Officer of BridgeBio.

Industry Context

This announcement is significant in the biopharmaceutical industry, particularly in the area of genetic diseases. The positive clinical trial results for acoramidis and the substantial funding secured position BridgeBio as a key player in this space. The partnership with Kyowa Kirin also highlights the growing interest in rare disease treatments in the Japanese market.

Comparison to Industry Standards

• The 81% survival rate on acoramidis in the ATTRibute-CM trial is comparable to the survival rate in the age-matched U.S. database (~85%), suggesting a significant clinical benefit.
• The 0.29 mean annual CVH rate on acoramidis is also comparable to the annual hospitalization rate observed in the broader U.S. Medicare population (~0.26).
• The $1.25 billion capital raise is substantial and positions BridgeBio well compared to other companies in the same stage of development.
• The licensing deal with Kyowa Kirin for $100 million upfront is a significant deal in the rare disease space, comparable to other licensing agreements for similar stage assets.

Stakeholder Impact

• Shareholders will benefit from the positive clinical trial results and the secured funding.
• Patients with ATTR-CM may have a new treatment option with acoramidis.
• Employees may benefit from the company's growth and financial stability.
• The partnership with Kyowa Kirin may lead to new opportunities for the company.

Next Steps

• The company will focus on the potential launch of acoramidis.
• They will continue to enroll patients in the ongoing Phase 3 clinical trials for infigratinib, BBP-418, and encaleret.
• The company plans to present additional detailed results of the ATTRibute-CM study at 2024 medical meetings.
• They anticipate sharing topline data from the CALIBRATE trial in 2025.
• The company will initiate a clinical program for hypochondroplasia in 2024.

Key Dates

Keywords

acoramidis, ATTR-CM, infigratinib, achondroplasia, BBP-418, LGMD2I, encaleret, ADH1, FDA, EMA, clinical trials, biopharmaceutical, genetic diseases, funding, royalty, Kyowa Kirin